Last reviewed 2026-04-20 · How we verify

(-)-Atenolol (ESATENOLOL)

Phase 2 active Small molecule

(-)-Atenolol (generic name: ESATENOLOL) is a s-atenolol drug. It is currently in Phase 2 development.

ESATENOLOL works by binding to the adenosine receptor A3, which can affect various physiological processes.

-)-Atenolol (ESATENOLOL) is a small molecule drug that targets the adenosine receptor A3. It belongs to the s-atenolol class and its mechanism of action is not well-documented. There is limited information available on its commercial status, approved indications, and pharmacokinetic properties. Further research is needed to fully understand the properties and potential uses of this compound. As a result, it is not clear if it is patented or available as a generic medication.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ESATENOLOL
Drug class	s-atenolol
Target	Adenosine receptor A3, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Think of adenosine like a messenger in your body that helps regulate different functions. When ESATENOLOL binds to the adenosine receptor A3, it can influence how this messenger works, potentially leading to changes in heart rate, blood pressure, or other bodily responses.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

(-)-Atenolol CI brief — competitive landscape report
(-)-Atenolol updates RSS · CI watch RSS

Frequently asked questions about (-)-Atenolol

What is (-)-Atenolol?

(-)-Atenolol (ESATENOLOL) is a s-atenolol drug.

How does (-)-Atenolol work?

ESATENOLOL works by binding to the adenosine receptor A3, which can affect various physiological processes.

What is the generic name of (-)-Atenolol?

ESATENOLOL is the generic (nonproprietary) name of (-)-Atenolol.

What drug class is (-)-Atenolol in?

(-)-Atenolol belongs to the s-atenolol class. See all s-atenolol drugs at /class/s-atenolol.

What development phase is (-)-Atenolol in?

(-)-Atenolol is in Phase 2.

What does (-)-Atenolol target?

(-)-Atenolol targets Adenosine receptor A3, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor and is a s-atenolol.

Drug class: All s-atenolol drugs
Target: All drugs targeting Adenosine receptor A3, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Therapeutic area: All drugs in Cardiovascular

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing